Details for Menveo vaccine and its components.
Registered for use in people aged ≥2 months.
MenACWY-CRM — quadrivalent meningococcal (serogroups A, C, W-135, Y)–CRM197 conjugate vaccine
Lyophilised powder containing serogroup A in a monodose vial with a pre-filled syringe or vial containing serogroups C, W-135 and Y in saline suspension.
Each 0.5 mL reconstituted dose contains:
- 10 µg meningococcal polysaccharide serogroup A conjugated to 16.7–33.3 µg Corynebacterium diphtheriae CRM197 protein
- 5 µg meningococcal polysaccharide serogroup C conjugated to 7.1–12.5 µg C. diphtheriae CRM197 protein
- 5 µg meningococcal polysaccharide serogroup W-135 conjugated to 3.3–8.3 µg C. diphtheriae CRM197 protein
- 5 µg meningococcal polysaccharide serogroup Y conjugated to 5.6–10 µg C. diphtheriae CRM197 protein
Also contains traces of:
- natural rubber
For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/menveo.